Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Non-invasive breast cancer (NIBC) is a type of breast cancer that has not spread beyond the milk ducts or lobules where it originated. This form of breast cancer is considered a pre-cancerous condition, as it has the potential to develop into invasive breast cancer (IBC) if left untreated. At Alfa Cytology, our team of experienced biologists work with you to develop non-invasive breast cancer therapeutics.
The progression from non-invasive to invasive breast cancer is a complex and multifaceted process that requires a comprehensive understanding of the underlying biological mechanisms. The transition from NIBC to IBC is a complex and multifaceted process that involves various genetic and molecular alterations within the affected cells.
Fig.1 Proposed models of DCIS progression. (Wang J., et al. 2024)
Studies have shown that certain molecular signatures, such as the overexpression of specific oncogenes or the loss of tumor suppressor genes, can increase the likelihood of non-invasive breast cancer progressing to an invasive form. Understanding these molecular and cellular underlying mechanisms in the transition from NIBC to IBC is critical for developing therapeutic and personalized strategies.
The current treatment of NIBC remains controversial due to uncertainty about the risk of progression to IBC or recurrence. The main goal of treatment is to prevent the development of potentially progressive non-invasive breast cancer into malignant IBC and future recurrence.
We summarize here all current treatments and relevant clinical trials for NIBC.
| NCT | Therapy | Trial Name | NIBC Feature | Phase |
| NCT00072462 | Endocrine Therapy | IBIS II DCIS | HR-positive DCIS | |
| NCT02005887 | TREND | NIBC | ||
| NCT02926911 | Active Surveillance | COMET | Low risk DCIS | Not Applicable |
At Alfa Cytology, we are committed to advancing the field of non-invasive breast cancer research. Our comprehensive suite of services encompasses the full spectrum of preclinical research, from target identification and validation to the evaluation of novel therapeutic strategies. Ductal carcinoma in situ (DCIS) is a non-invasive form of breast cancer that is considered a precursor to IBC. We also provide one-stop solutions for ductal carcinoma in situ (DCIS).
 In Vitro Models |
 Animal Models |
|
|
If you are interested in learning more about Alfa Cytology's services or our ongoing research in non-invasive breast cancer, please don't hesitate to contact us. Our team of experts is dedicated to providing personalized solutions and support to help you achieve your research and development goals. We look forward to the opportunity to discuss how we can collaborate to advance the field of non-invasive breast cancer research.
Reference
